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Graphical abstract
A cellular protease-mediated graphene-based nanosystem is developed for co-delivery of a 
membrane-associated cytokine (TRAIL) and an intracellular-acting small-molecule drug (DOX). 
The nanocarrier realizes the intramembrane enzyme-mediated extracellular release of TRAIL and 
endocytotic acidity-responsive intracellular release of DOX, which enables them to target to their 
distinct sites of action. This formulation starts a new generation of 2D nanomaterials with 
programmed-release therapeutics capability for combination cancer treatment.
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Combination cancer therapy has attracted considerable attentions due to its advantages of 
enhancing therapeutic efficacy, decreasing possibility of drug resistance and reducing side 
effects over monotherapy.[1] Co-encapsulation of multiple anticancer agents in one single 
nanocarrier can optimize their pharmacokinetic profiles and biodistribution behaviors in a 
spatiotemporal co-delivery fashion, resulting in a more efficient synergistic antitumor 
activity, compared to the conventional “cocktail”-based drug mixtures.[2] For example, 
irinotecan/floxuridine co-loaded liposome has proved to be more effective than the cocktails 
of individual free and liposomal drugs in both animal tumor models and patients with 
advanced solid tumors concordantly.[3]
Co-delivery systems incorporating therapeutic protein/peptides with small-molecule drugs or 
macromolecular nuclear acids has also been validated as a promising strategy for 
enhancement of cancer treatment.[4] Different from small-molecule drugs and nuclear acids 
that mostly function within the cells, the action sites of proteins are mainly classified to be 
localized on the cell membrane and inside the cells, respectively. For instance, tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a typical membrane-
associated cytokine, acts on the death receptor on the cell membrane for induction of 
apoptosis,[5] while caspase 3 takes effect in the cytoplasm to activate the caspase-mediated 
apoptosis.[6] However, a co-delivery system capable of differentiating the extracellular and 
intracellular targets still remains elusive. In our previous work, we have developed a gel-
liposome-based system for sequential and site-specific co-delivery of TRAIL and 
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doxorubicin (DOX), a small-molecule anticancer drug. This formulation was limited by 
relatively low drug-loading capacity and undesirable leakage of physically-encapsulated 
protein.[4d]
We herein report a new graphene-based co-delivery nanosystem of a cell-membrane-targeted 
anticancer protein and a chemotherapeutic agent for combination cancer treatment (Figure 
1). This designed nanocarrier is composed of graphene oxide (GO), polyethylene glycol 
(PEG) linker and a furin-cleavable peptide, which is achieved by step-by-step site-specific 
conjugations (Figure 1a). The GO nanosheet is applied to bear DOX due to a strong 
supramolecular π-π stacking interaction between GO and DOX.[7] A heterobifunctional 
PEG linker containing amino and azide terminal groups (NH2-PEG-N3) was first utilized for 
connection between the carboxylated GO (GO-COOH) nanosheet and the furin-cleavable 
peptide, which also provides a good dispersity and stability of GO nanosheet due to the high 
hydrophilicity of the long PEG chain. The alkynylated peptide sequence in a typical form of 
RX(K/R)RY (R: arginine; K: lysine; X: any amino acid; Y: the cleavage site) is linked to the 
PEG chain via a click chemistry reaction, which can be specifically recognized and cleaved 
by furin, a protease highly expressed on the cell membrane and Golgi complex of many 
cancer cells.[8] Finally, tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL), that acts on the death receptor on the cell membrane to activate apoptosis-
mediated cell death, is conjugated to the sulfhydryl (cysteine) groups of the peptide using an 
amine-to-sulfhydryl crosslinker. Of note, TRAIL itself can also serve as “targeting ligand” 
for the whole delivery system.[9]
The GO-based nanocarrier preferentially accumulates at the tumor site by means of the 
enhanced permeability and retention (EPR) effect after intravenous administration, and 
covered on the tumor cells along with the binding of TRAIL on the death receptor.[5c, 10] 
The plasma membrane-located furin digests the peptide linker, which results in the 
extracellular release of TRAIL and prevents its internalization together with the GO into the 
cancer cells for enhanced apoptosis induction. The GO nanosheet carrying DOX is then 
internalized into the cells.[11] In the endosomes, the acidic endocytotic vesicles, the release 
of DOX is promoted as expected, resulting from the increased solubility of protonated DOX 
in the acidic environment. The intracellularly released DOX specifically accumulates into 
the nuclei to produce DNA damage-mediated cytotoxicity,[12] which combines with the 
apoptosis-inducing effect of TRAIL for an optimal synergistic antitumor activity (Figure 
1b).
To substantiate our design, we first synthesized TRAIL/DOX-fGO using a sequential and 
site-specific conjugation technique (Figure S1a in the Supporting Information). A nano-
sized GO sheet was obtained after ultrasonication and purification, which had an average 
size of 152 nm determined by the dynamic light scattering measurement[13] (Figure S2a). 
The atomic force microscope (AFM) imaging showed a typical two-dimensional (2D) 
appearance of GO with the thickness of 2 nm (Figure 2a). The GO nanosheet was then 
carboxylated and conjugated with NH2-PEG-N3 via carbodiimide catalyzed amide 
formation.[14] PEGylation was confirmed by the infrared spectroscopy (Figure S3). Upon 
the click chemistry-mediated linkage between the furin-cleavable peptide and the PEG 
chain, TRAIL was conjugated to the sulfhydryl group of cysteine in the peptide using an 
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amino- and sulfhydryl-directed heterobifunctional crosslinker (Sulfo-SMCC) to acquire 
TRAIL-conjugated furin-cleavable GO (TRAIL-fGO). After incubation of TRAIL-fGO with 
triethylamine (TEA)-treated DOX, the DOX-loaded and TRAIL-conjugated furin-cleavable 
GO (TRAIL/DOX-fGO) was obtained by centrifugal filtration to remove the excessive TEA 
and unbound DOX (Figure S4a), which had an average size of 194 nm (Figure S2b) and a 
DOX-loading capacity up to 43.8%, far exceeding that of many lipid- and polymer-based 
nanocarriers. TRAIL/DOX-fGO with the long PEG chain (molecular weight: 5000 Da) 
showed higher stability than both GO and TRAIL/DOX-fGO with the short PEG chain 
(molecular weight: 350 Da) in the culture medium containing 10% fetal bovine serum 
(Figure S4b, c). The AFM image showed that TRAIL/DOX-fGO had a lateral width of less 
than 200 nm and a topological height of over 8 nm (Figure 2a), which was significantly 
higher than that of the PEG-GO conjugate as about 5 nm (Figure S5), suggesting the 
conjugation of the peptide-linked TRAIL on the PEG-modified GO nanosheet. Additionally, 
the TRAIL conjugation was assessed using the protein displacement method (Figure S6). No 
significant change in the fluorescence intensity of rTRAIL was found in the filtrate after 
centrifugal filtration following the incubation of rTRAIL-fGO with different concentrations 
of bovine serum albumin for 1 h, which further indicated that TRAIL was conjugated on the 
surface of GO.
To evaluate the furin-mediated release of TRAIL, we determined the in vitro release profile 
of rhodamine-labeled TRAIL (rTRAIL) from rTRAIL-fGO in the presence and absence of 
furin using a centrifuge filter tube (Figure 2b). Only 4.8% of rTRAIL was detected within 2 
h in the absence of furin. In sharp contrast, 11.7% of rTRAIL was released from rTRAIL-
fGO in the first 6 min after incubation with furin, and nearly 52.9% was released within 2 h. 
Furthermore, we have utilized rTRAIL-conjugated GO without furin-cleavable substrate 
(rTRAIL-nGO) as a control (Figure S1b). After 24 h of incubation with furin, the cumulative 
amount of rTRAIL released from rTRAIL-nGO was determined to be only 7.8%. It was 
suggested that the specific peptide linker between TRAIL and GO could be efficiently 
cleaved by furin and therefore led to the release of TRAIL. The circular dichroism spectrum 
of the released TRAIL was consistent with that of the native TRAIL (Figure S7), indicating 
that this furin-directed peptide degradation had no impact on the protein secondary structure 
of TRAIL. In addition, the release behavior of DOX from TRAIL/DOX-fGO was tested 
using a dialysis tube (Figure 2c). TRAIL/DOX-fGO displayed extremely higher DOX 
release rate at pH 5.5 than pH 7.4, implying that when TRAIL/DOX-fGO was endocytosed 
into the endosome, the acidic environment allowed the promoted release of DOX inside 
rather than outside the cells.
Next, the human lung adenocarcinoma epithelial (A549) cells that express sufficient furin[15] 
were applied as a cell model to investigate the site-specific delivery of TRAIL and DOX by 
TRAIL/DOX-fGO. The furin-deficient LoVo cells, the human colon adenocarcinoma cells, 
were taken as a control.[16] We first determined the level of furin expression on the cancer 
cells using the immunofluorescence staining (Figure 3a and Figure S8). As expected, 
endoprotease furin (red) was apparently detected to be localized both on the cell membranes 
(green) and within the cytosol of A549 cells, whereas few were found in LoVo cells. To 
validate that the membrane-localized furin was able to degrade the peptide, thus causing the 
released TRAIL bind onto the plasma membrane, A549 and LoVo cells were incubated with 
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rTRAIL-fGO or rTRAIL-nGO for 2 h, followed by the confocal laser scanning microscope 
(CLSM) observation (Figure 3b and Figure S9). An evident difference in the distribution of 
rTRAIL delivered by rTRAIL-fGO and rTRAIL-nGO was observed in A549 cells. A large 
number of rTRAIL (red) bound to the cell membrane (green) after incubation with rTRAIL-
fGO, while most of rTRAIL was detected within the cells that were treated with rTRAIL-
nGO, which indicated that the conjugated TRAIL on nGO without the furin-cleavable site 
was inevitably internalized with GO into the cell, but the released TRAIL from TRAIL-fGO 
mediated by the cell surface furin could efficiently bind onto the cell membrane for 
enhanced apoptosis-inducing effect. On the contrary, for LoVo cells, rTRAIL of both 
formulations was mainly monitored inside the cells, further confirming the furin-mediated 
extracellular release and membrane binding of TRAIL.
To assess the endocytotic capability of TRAIL/DOX-fGO, we compared the cellular uptake 
of TRAIL/DOX-fGO on A549 cells at 37 °C and 4 °C (Figure S10). The uptake of TRAIL/
DOX-fGO was significantly inhibited at 4 °C, suggesting that the GO nanocarrier permeated 
into the cells through a typical internalization pathway. The intracellular distribution of DOX 
in A549 cells was evaluated using CLSM (Figure 3c and Figure S11). After the cells were 
incubated for 3 h, the DOX signal (red) evenly distributed within the cells, suggesting that 
TRAIL/DOX-fGO was taken up by the cells. As time increased to 6 h, DOX was released 
from the GO nanosheet and accumulated into the nuclei (blue). After 9 h of incubation, most 
of DOX showed nucleus targeting as visualized by the magenta fluorescence for subsequent 
DNA damage-induced apoptosis.
The synergistic apoptosis-inducing activities of TRAIL and DOX delivered site-specifically 
by TRAIL/DOX-fGO were evaluated toward A549 cells using the FITC (fluorescein 
isothiocyanate) active caspase 3 apoptosis kit and the Annexin-FITC apoptosis detection kit, 
respectively. Caspase 3, known as an effector for death signal, has a central effect on the 
execution phase of cell apoptosis. As shown in Figure 4a, the fluorescence signal (green) 
was hardly detected within the cells after treated with TRAIL-fGO; this is because A549 
cells were TRAIL resistant and did not show a clear evidence of apoptosis even at a high 
concentration of TRAIL.[17] Chemotherapeutic agents including DOX can sensitize TRAIL-
resistant A549 cells to TRAIL-mediated apoptosis.[18] It has been validated that the uptake 
of anticancer drugs remarkably increased the expression of death receptors in a variety of 
cancer cells for enhanced apoptotic effects.[19] The combination treatment of TRAIL and 
DOX using TRAIL/DOX-nGO on A549 cells resulted in a stronger green fluorescence 
signal from the active caspase 3 in the cytosol. Of note, TRAIL/DOX-fGO compared to 
TRAIL/DOX-nGO presented a significantly greater apoptosis-inducing capability, arising 
from the apoptosis-enhancement by TRAIL that was targetedly delivered on the cell 
membrane by fGO, combined with the apoptosis-sensitization by DOX. Furthermore, the 
quantitative determination results obtained from the Annexin V-FITC/PI (propidium iodide) 
detection assay verified the optimal synergistic apoptotic efficacy of TRAIL/DOX-fGO 
(Figure 4b). TRAIL/DOX-fGO showed the highest total apoptotic ratio of 17.6% (a sum of 
the early apoptotic ratio of 13.5% and the late apoptotic ratio of 4.1%) and the lowest 
viability of 77.8% compared to other formulations.
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The in vitro cytotoxicity of TRAIL/DOX-fGO against A549 cells were examined using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Figure 4c). The 
half-maximal inhibitory concentration (IC50) of TRAIL-fGO on A549 cells was 119 ng/mL, 
suggesting the TRAIL-insensitivity of A549 cells, while IC50 of DOX-fGO was 509 ng/mL. 
In comparison, TRAIL/DOX-nGO showed increased cytotoxicity with decreased IC50 of 33 
ng/mL (TRAIL concentration) and 329 ng/mL (DOX concentration). More significantly, 
IC50 of TRAIL/DOX-fGO was determined to be 14 ng/mL (TRAIL concentration) and 140 
ng/mL (DOX concentration), which increased cytotoxicities of TRAIL-fGO, DOX-fGO and 
TRAIL/DOX-fGO to 8.5-, 3.6- and 2.4-fold, respectively. We next compared the 
cytotoxicities of TRAIL/DOX-fGO and TRAIL/DOX-nGO against the furin-deficient LoVo 
cells (Figure 4d). TRAIL/DOX-fGO showed a comparable cytotoxicity with IC50 of 759 
ng/mL (DOX concentration) to 884 ng/mL of TRAIL/DOX-nGO, due to the similar 
transportation property of TRAIL/DOX-fGO and TRAIL/DOX-nGO toward LoVo cells, 
which further evidenced that the important role of furin-mediated membrane-targeted 
delivery of TRAIL by fGO on enhanced synergistic anticancer activity with DOX. In 
addition, the blank fGO without TRAIL and DOX had negligible cytotoxicities on both 
A549 and LoVo cells at all the studied concentrations (Figure S12). Taken together, the 
specific delivery of TRAIL and DOX to their distinct sites of action supports the 
improvement on their combination cytotoxicity.
To explore the tumor-targeting capability of the GO nanocarrier, the in vivo biodistribution 
of Cy5.5-labeled TRAIL-conjugated fGO (Cy5.5-TRAIL-fGO) after intravenous 
administration into the A549 tumor-bearing nude mice was monitored using a non-invasive 
optical imaging technique. As displayed in Figure 5a, after administration for 4 h, a strong 
fluorescence signal of Cy5.5-TRAIL-fGO was obviously detected at the tumor site. As time 
extended, Cy5.5-TRAIL-fGO showed a higher Cy5.5 signal in the tumor than in the normal 
tissues after administration for 24 h, suggesting a remarkable tumor targetability of the GO 
nanosheet. At 24 h post administration, the mice were sacrificed. The tumor and normal 
organs were harvested, followed by the ex vivo imaging. The strongest fluorescence signal 
was observed at the tumor compared to other normal organs (Figure 5b), which was in 
agreement with the quantitative region-of-interest (ROI) analysis (Figure 5c). The 
fluorescence intensity of Cy5.5 at the tumor tissue was 8.14-, 3.5-, 10.7-, 5.1- and 1.1-fold 
that at heart, liver, spleen, lung and kidney, respectively. Collectively, it was confirmed that 
TRAIL/DOX-fGO allowed the high accumulation of drugs at the tumor site via a 
combination of passive and active targeting effects.
The in vivo antitumor efficacy of TRAIL/DOX-fGO was investigated on the A549 tumor-
bearing nude mice. As shown in Figure 5d, the growth of tumor was significantly inhibited 
after the mice were successively treated with different DOX formulations including DOX-
fGO, TRAIL/DOX-nGO and TRAIL/DOX-fGO, except TRAIL-fGO due to the A549 tumor 
resistant to TRAIL, compared to phosphate buffered saline (PBS) as a negative control. 
TRAIL/DOX-nGO showed a stronger tumor inhibition capability than DOX-fGO, indicating 
that the synergistic antitumor activity by a combination of TRAIL and DOX. It is notable 
that TRAIL/DOX-fGO brought about the strongest effect on suppressing the tumor growth, 
which substantiated that site-specific delivery of TRAIL and DOX by TRAIL/DOX-fGO 
enabled the reinforcement on the synergistic therapeutic efficacy. The images and weights of 
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tumors harvested from the mice after treatment further indicated the most significant tumor 
size shrinking caused by TRAIL/DOX-fGO (Figure 5e and Figure S13a). No noticeable 
change in the body weight of the mice was monitored during the treatment of TRAIL/DOX-
fGO (Figure S13b). We further applied the hematoxylin and eosin (HE) and the terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining to evaluate the 
antitumor efficiency of TRAIL/DOX-fGO, respectively (Figure S14a). The images of HE-
stained tumor tissue presented that a massive remission of tumor cells occurred after the 
mice were treated with TRAIL/DOX-fGO. The fluorescence images obtained from the in 
situ TUNEL staining showed that the highest level of the AlexaFluor 488-stained apoptotic 
DNA fragmentation (green) in the tumor tissue of the mice receiving TRAIL/DOX-fGO, 
suggesting that the pronounced inhibition on tumor growth was attributed mainly to the 
elevated apoptosis induced by TRAIL/DOX-fGO. Additionally, the histologic images of 
other organs, such as heart, liver, spleen, lung, kidney, collected from the mice treated with 
TRAIL/DOX-fGO exhibited no obvious pathological abnormalities in all the studied normal 
organs compared to those treated with PBS (Figure S14b).
In summary, we have developed a sequentially-functionalized GO nanostructure as a new 
cellular protease-mediated programmed co-delivery system integrating membrane-related 
proteins and intracellular-functioning small-molecule drugs. Such GO nanocarrier was able 
to efficiently release its cargoes, TRAIL and DOX to their distinct sites of action separately, 
in a site-specific manner. We believe that it will start a new generation of 2D nanomaterials 
with programmed-release therapeutics capability for combination cancer treatment with 
enhanced efficacy.
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Schematic design of the cellular protease-mediated graphene-based co-delivery system. a) 
Main components of TRAIL/DOX-fGO, consisting of DOX-loaded GO, PEG linker and 
TRAIL-conjugated furin-cleavable peptide. b) Site-specific delivery of TRAIL to cell 
membrane and DOX to nuclei for enhanced synergistic cancer treatment. i: intravenous 
administration of GO; ii: accumulation of GO at the tumor site through passive and active 
targeting effects; iii: TRAIL binding on the death receptor and degradation of peptide linker 
by furin on the cell membrane; iv: activation of caspase-mediated apoptosis; v: induction of 
cell death; vi: endocytosis of GO by the tumor cells; vii: acid-promoted DOX release in 
endosome; viii: accumulation of released DOX into nucleus; ix: induction of DNA damage-
mediated apoptosis and cytotoxicity.
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a) AFM images of GO and TRAIL/DOX-fGO. Scale bars indicate 200 nm. b) In vitro 
release profiles of rTRAIL from rTRAIL-fGO or rTRAIL-nGO in the absence and presence 
of furin. c) In vitro release profiles of DOX from rTRAIL/DOX-fGO at pH 7.4 and 5.5.
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a) CLSM images of A549 and LoVo cells after immunofluorescence staining with the furin 
antibody and the rhodamine-labeled secondary antibody. The cell membranes were stained 
with AF488-WGA. Red: furin; Green: cell membrane. Scale bars indicate 10 µm. b) CLSM 
images of A549 and LoVo cells after incubation with rTRAIL-fGO for 2 h. The cell 
membranes were stained with AF488-WGA. Red: rTRAIL; Green: cell membrane. Scale 
bars indicate 10 µm. c) CLSM images of A549 cells after incubation with TRAIL/DOX-fGO 
for different time. The nuclei were stained with Hoechst 33342. Red: DOX; Blue: nuclei. 
Scale bars indicate 20 µm.
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a) CLSM images of A549 cells stained with FITC-labeled active caspase 3 antibody after 
treated with different formulations. The nuclei were stained with Hoechst 33342. Green: 
active caspase 3; Blue: nuclei. Scale bars are 40 µm. b) Flow cytometric analysis of A549 
cell apoptosis induced by different formulations. The dot plots represent the typical viable 
and apoptotic cell populations (%) obtained using Annexin V-FITC/PI staining. c) In vitro 
cytotoxicity of different formulations against A549 cells for 48 h. d) In vitro cytotoxicity of 
TRAIL/DOX-fGO and TRAIL/DOX-nGO against LoVo cells for 48 h.
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a) In vivo fluorescence imaging of the A549 tumor-bearing nude mice at 4, 12, 24 h after 
intravenous administration of Cy5.5-TRAIL-fGO (30 nmol/kg Cy5.5). Red arrow indicates 
the tumor site. b) Ex vivo fluorescence imaging of the tumor and normal organs collected 
from the mice at 24 h after administration. 1: heart; 2: liver; 3: spleen; 4: lung; 5: kidney; 6: 
tumor. c) ROI analysis of fluorescent signals of the tumor and normal organs. d) The A549 
tumor growth curves of the mice after treatment with different formulations (0.16 mg/kg 
TRAIL, 2 mg/kg DOX). *P < 0.05, **P < 0.01. e) The representative images of the A549 
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xenograft tumors collected from the mice after treatment with different formulations at Day 
12. i: PBS; ii: TRAIL-fGO; iii: DOX-fGO; iv: TRAIL/DOX-nGO; v: TRAIL/DOX-fGO.
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